Display Post Content

SNAC is redefining conventional neuroimaging by using cutting edge AI algorithms to bring unparalleled speed, unbiased accuracy and improved consistency to transform the medical imaging industry. The images here is a side by side comparison of multiple sclerosis lesion segmentation. Left images shows manual lesion segmentation, while right shows fully automated lesion segmentation. Image curtesy of SNAC.




SNAC uses structural and advanced image analysis to further the understanding of neurological disorders, and develop tailored imaging biomarkers for clinical trials of emerging therapeutics. Our quantitative biomarker research has been translated to Phase 2 clinical trials of emerging pro-remyelinating therapies; and composite MRI-electrophysiology studies has yielded new insights into sub-clinical, disease-related injury to brain structure-function networks. The recent incorporation of AI into SNAC’s research pipelines, rapidly accelerate the development of neuroimaging ‘smarts’ for both clinical trials and the diagnostic imaging industry.